Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:12
  • preuzimanja u poslednjih 30 dana:5

Sadržaj

članak: 2 od 11  
Back povratak na rezultate
2020, vol. 77, br. 9, str. 885-892
Preživljavanje hirurški lečenih bolesnika sa odmaklim karcinomom larinksa u Srbiji
aKlinički centar Srbije, Klinika za ORL i MFH, Beograd + Univerzitet u Beogradu, Medicinski fakultet, Katedra Otorinolaringologija sa maksilofacijalnom hirurgijom
bGeneral Hospital Loznica, Loznica
cGeneral Hospital "Dr Đorđe Jovanović", Zrenjanin
dUniverzitet u Beogradu, Medicinski fakultet, Institut za farmakologiju, kliničku farmakologiju i toksikologiju
eKlinički centar Srbije, Klinika za fizikalnu medicinu i rehabilitaciju, Beograd
fKlinički centar Srbije, Centar za radiologiju i magnetnu rezonancu, Beograd
gKlinički centar Srbije, Centar za nuklearnu medicinu, Beograd

e-adresaanajotic@yahoo.com
Sažetak
Uvod/Cilj. Karcinomi larinksa čine 1%-3% svih maligniteta glave i vrata. Terapijski rezultati i preživljavanje umnogome zavise od stadijuma bolesti. Cilj rada bio je da se ispita preživljavanje bolesnika, hirurški lečenih od odmaklih karcinoma larinksa, u zavisnosti od starosti, pola, uobičajenih faktora rizika (pušenje, konzumiranje alkohola), primarne lokalizacije tumora, patohistološkog stadijuma bolesti, tumor, nodus, metastaza (TNM) stadijuma bolesti, i primenjene hirurške terapije bolesti. Metode. Retrospektivnom studijom bilo je obuhvaćeno 252 bolesnika, hirurški lečenih od odmaklih karcinoma glave i vrata, sa periodom praćenja od pet godina. Bolesnici uključeni u studiju primarno su lečeni hirurški, sa sprovođenjem postoperativne radio i hemioterapije, u zavisnosti od lokalne i regionalne proširenosti bolesti, intraoperativnog nalaza i granica linija resekcija. Petogodišnje ukupno preživljavanje i preživljavanje bez znakova bolesti računato je u zavisnosti od demografskih i kliničkih karakteristika bolesnika. Rezultati. Ukupno petogodišnje preživljavanje bolesnika sa odmaklim karcinomima larinksa je iznosilo 86,14%, a petogodišnje preživljavanje bez znakova bolesti 86,51%. Smanjeno preživljavanje bilo je značajno povezano sa starošću bolesnika, višim histološkim gradusom tumora i opsežnijim disekcijama vrata. Zaključak. Primarna totalna laringektomija rezultira dužim preživljavanjem u slučajevima transglotisnih T3 i T4a tumora larinksa. Pre donešenja odluke, bolesnici bi trebali biti informisani o mogućim većim rizicima od smrtnog ishoda povezanim sa izborom hirurške metode i drugih načina lečenja.
Reference
Andersen, P.E., Warren, F., Spiro, J., Burningham, A., Wong, R., Wax, M.K., Shah, J.P., Cohen, J.I. (2002) Results of selective neck dissection in management of the node-positive neck. Archives of Otolaryngology - Head & Neck Surgery, 128(10): 1180-1184
Brandstorp-Boesen, J., Sørum, F.R., Boysen, M., Brøndbo, K. (2017) Impact of stage, management and recurrence on survival rates in laryngeal cancer. PLoS One, 14; 12(7): e0179371
Chen, A.Y., Halpern, M. (2007) Factors predictive of survival in advanced laryngeal cancer. Archives of Otolaryngology - Head & Neck Surgery, 133(12): 1270-1276
Corazziari, I., Quinn, M., Capocaccia, R. (2004) Standard cancer patient population for age standardising survival ratios. European Journal of Cancer, 40(15): 2307-2316
Cosetti, M., Yu, G., Schantz, S.P. (2008) Five-year survival rates and time trends of laryngeal cancer in the US population. Archives of Otolaryngology - Head & Neck Surgery, 134(4): 370-379
de Graeff, A., de Leeuw, J.R.J., Ros, W.J.G., Hordijk, G.J., Blijham, G.H., Winnubst, J.A.M. (2001) Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. European Journal of Cancer, 37(3): 332-339
Dyckhoff, G., Plinkert, P.K., Ramroth, H.A. (2017) Change in the study evaluation paradigm reveals that larynx preservation compromises survival in T4 laryngeal cancer patients. BMC Cancer, 17(1): 609
Dziegielewski, P.T., O'Connell, D.A., Klein, M., Fung, C., Singh, P., Alex, M.M., i dr. (2012) Primary total laryngectomy versus organ preservation for T3/T4a laryngeal cancer: A population-based analysis of survival. J Otolaryngol Head Neck Surg, 41 Suppl 1: S56-64
Đorđević, V., Milovanović, J., Petrović, Ž., Dudvarski, Z., Petrović, B., Stanković, P. (2004) Radikalna hirurgija malignih tumora larinksa. Acta chirurgica iugoslavica, vol. 51, br. 1, str. 31-35
Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., i dr. (2013) GLOBOCAN 2012 v 1.0: Cancer incidence and mortality worldwide. u: IARC Cancer Base, Lyon, France: International Agency for Research on Cancer, No. 11, http://globocan.iarc.fr
Ferlito, A., Silver, C.E., Rinaldo, A. (2008) Selective neck dissection (IIA, III): A rational replacement for complete functional neck dissection in patients with N0 supraglottic and glottic squamous carcinoma. Laryngoscope, 118(4): 676-679
Forastiere, A.A., Goepfert, H., Maor, M., Pajak, T.F., Weber, R., Morrison, W., Glisson, B., Trotti, A., Ridge, J.A., Chao, C., Peters, G., Lee, D., Leaf, A., Ensley, J., Cooper, J. (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. New England Journal of Medicine, 349(22): 2091-2098
Francis, E., Matar, N., Khoueir, N., Nassif, C., Farah, C., Haddad, A. (2014) T4a laryngeal cancer survival: Retrospective institutional analysis and systematic review. Laryngoscope, 124(7): 1618-1623
Hoffman, H.T., Porter, K., Karnell, L.H., Cooper, J.S., Weber, R.S., Langer, C.J., Ang, K., Gay, G., Stewart, A., Robinson, R.A. (2006) Laryngeal cancer in the United States: Changes in demographics, patterns of care, and survival. Laryngoscope, 116(9 Pt 2 Suppl 111): 1-13
Krejović, B. (1981) The importance of surgery in treatment of malignant laryngeal tumors. Belgrade: Medical Faculty, dissertation (Serbian)
Megwalu, U.C., Sikora, A.G. (2014) Survival outcomes in advanced laryngeal cancer. JAMA Otolaryngology - Head & Neck Surgery, 140(9): 855-860
National Comprehensive Cancer Network Head and neck cancers. Version 1.2017, http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf [accessed 2017 September]
Olsen, K.D. (2009) Reexamining the treatment of advanced laryngeal cancer. Head & Neck, 32(1): 1-7
Richard, J.M., Sancho-Garnier, H., Pessey, J.J., Luboinski, B., Lefebvre, J.L., Dehesdin, D., Stromboni-Luboinski, M., Hill, C. (1998) Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncology, 34(3): 224-228
Saini, A.T., Genden, E.M., Megwalu, U.C. (2016) Sociodemographic disparities in choice of therapy and survival in advanced laryngeal cancer. American Journal of Otolaryngology, 37(2): 65-69
Sher, D.J., Adelstein, D.J., Bajaj, G.K., Brizel, D.M., Cohen, E.E.W., Halthore, A., Harrison, L.B., Lu, C., Moeller, B.J., Quon, H., Rocco, J.W., Sturgis, E.M., Tishler, R.B., Trotti, A., Waldron, J. (2017) Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO evidence-based clinical practice guideline. Practical Radiation Oncology, 7(4): 246-253
Stanković, M., Milisavljević, D., Stojanov, D., Živić, M., Živaljević, S., Stanković, I., i dr. (2012) Influential factors, complications and survival rate of primary and salvage total laryngectomy for advanced laryngeal cancer. Coll Antropol, 36(Suppl 2): 7-12
Suárez, C., Rodrigo, J.P., Robbins, K. T., Paleri, V., Silver, C.E., Rinaldo, A., Medina, J.E., Hamoir, M., Sanabria, A., Mondin, V., Takes, R.P., Ferlito, A. (2013) Superselective neck dissection: rationale, indications, and results. European Archives of Oto-Rhino-Laryngology, 270(11): 2815-2821
Wolf, G.T., Fisher, S.G., Hong, W.K., Hillman, R., Spaulding, M., Laramore, G.E., i dr., Department of Veterans Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. New England Journal of Medicine, 324(24): 1685-1690
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.2298/VSP171226138M
objavljen u SCIndeksu: 09.10.2020.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0